Exploration of insights, opportunities and caveats provided by the X-ray structures of hSERT.
The recently reported X-ray structures of the human serotonin (5-HT) transporter SERT with bound inhibitors open new opportunities for drug discovery at SERT, selectivity design with respect to other neurotransmitter sodium transporters, and enhanced understanding of the molecular events involved in SERT action. Through computational and structural analyses, we explore the binding and migration of 5-HT at SERT. Consistent with earlier studies of leucine migration at the bacterial homolog of SERT, LeuT, we find multiple potential 'stopover' sites for 5-HT binding at SERT including the two (transmembrane S1 and extracellular vestibule S2) seen in the binding of the SSRI (S)-citalopram (S-Cit) to SERT, as well as other sites. Docking studies reveal the possibility of both hetero- (S-Cit+5-HT) and homo-dimeric (5-HT+5-HT) co-binding at both these sites which may explain earlier published allosteric activity observations and provide novel design strategies. Comparisons with substrate bound X-ray structures of the dopamine transporter reveal a number of potential sources of selectivity, some of which may be 'artificial' including target based, species related, experimental design related, and ligand dependent examples including substrate versus inhibitor related features.
3D-2Drug, LLC, PO Box 184, Fair Lawn, NJ, USA. Electronic address: sid.topiol@3D-2drug.com.
Sid
S
Topiol
Lundbeck Research, H. Lundbeck A/S, Copenhagen, Denmark.
Benny
B
Bang-Andersen
Translational Neuropsychiatry Unit, Clinical Medicine, Aarhus University, Denmark.
Connie
C
Sanchez
Formerly of Lundbeck Research, H. Lundbeck A/S, Copenhagen, Denmark.
Klaus P
KP
Bøgesø
D018360:Crystallography, X-Ray; D006801:Humans; D008958:Models, Molecular; D011487:Protein Conformation; D050486:Serotonin Plasma Membrane Transport Proteins / Q000737:chemistry*
D050486:Serotonin Plasma Membrane Transport Proteins
(S)-Citalopram; Computer-aided drug discovery; DAT; Docking; LeuT; SERT; Structure-based drug design; X-ray structure